Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
This funding opportunity supports research aimed at understanding how inflammasomes contribute to neurocognitive disorders and immune function in individuals with HIV and substance use disorders, encouraging innovative studies that link these areas to improve health outcomes.
The scientific objective of this Notice of Funding Opportunity is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes.
Award Range
Not specified - $500,000
Total Program Funding
Not specified
Number of Awards
Not specified
Matching Requirement
No
Eligible Applicants
Additional Requirements
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Geographic Eligibility
All
Application Opens
October 17, 2023
Application Closes
October 28, 2024
Grantor
U.S. Department of Health & Human Services (National Institutes of Health)
Subscribe to view contact details